Literature DB >> 8884181

Gangliosides GM1, GM2 and GM3 inhibit the platelet-derived growth factor-induced signalling transduction pathway in vascular smooth muscle cells by different mechanisms.

A Sachinidis1, R Kraus, C Seul, M K Meyer zu Brickwedde, K Schulte, Y Ko, J Hoppe, H Vetter.   

Abstract

Gangliosides appear to regulate proliferation of different cell types. In the present study, we investigated the effects of gangliosides GM1, GM2 and GM3 on platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell (VSMC) growth. In addition, we examined the effects of gangliosides on the PDGF-BB-dependent signalling transduction pathway in rat aortic VSMC. GM2 and GM1 inhibit the PDGF-BB-dependent receptor tyrosine autophosphorylation, stimulation of the PLC-gamma 1, increase of inositol-1,4,5-trisphosphate (InsP3), elevation in cytosolic free Ca2+ ([Ca2+]i), expression of the immediate early growth response gene c-fos and cell proliferation with the following rank order of potency GM2 > GM1. Although GM3 did not influence the PDGF-BB-dependent receptor autophosphorylation and PLC-gamma 1 activation, it effectively inhibited the PDGF-BB-dependent InsP3 formation, [Ca2+]i and cell growth. Binding studies with 125I-PDGF-BB on VSMC in the presence and absence of 10 to 50 microM of each ganglioside revealed that GM1 and GM2 effectively inhibited the specific binding of PDGF-BB with an IC50 value of 20 microM for GM2 and 30 microM for GM1. GM3 had no significant effect on the specific 125I-PDGF-BB binding. These observations suggest that GM1 and GM2 may interact with PDGF-BB or its receptor resulting in a prevention of its binding. GM3 was able to suppress the PDGF-BB-dependent increase of InsP3 and [Ca2+]i downstream of the PDGF-BB-dependent receptor autophosphorylation and PLC-gamma 1 activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884181

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  7 in total

1.  A ganglioside-specific sialyltransferase localizes to axons and non-Golgi structures in neurons.

Authors:  C A Stern; M Tiemeyer
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

2.  A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation.

Authors:  Luigi Boccuto; Kazuhiro Aoki; Heather Flanagan-Steet; Chin-Fu Chen; Xiang Fan; Frank Bartel; Marharyta Petukh; Ayla Pittman; Robert Saul; Alka Chaubey; Emil Alexov; Michael Tiemeyer; Richard Steet; Charles E Schwartz
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

3.  Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides.

Authors:  Elodie Masson; Nicolas Wiernsperger; Michel Lagarde; Samer El Bawab
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

4.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures.

Authors:  M Rusnati; E Tanghetti; C Urbinati; G Tulipano; S Marchesini; M Ziche; M Presta
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

Review 5.  Neurobiology and cellular pathogenesis of glycolipid storage diseases.

Authors:  Steven U Walkley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

Review 6.  The Roles of Glycans in Bladder Cancer.

Authors:  Yuli Jian; Zhongyang Xu; Chunyan Xu; Lin Zhang; Xiaoxin Sun; Deyong Yang; Shujing Wang
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

7.  5,8-Dimethoxy-2-Nonylamino-Naphthalene-1,4-Dione Inhibits Vascular Smooth Muscle Cell Proliferation by Blocking Autophosphorylation of PDGF-Receptor β.

Authors:  Yohan Kim; Jung-Jin Lee; Sang-Gil Lee; Sang-Hyuk Jung; Joo-Hui Han; So Young Yang; Eunju Yun; Gyu-Yong Song; Chang-Seon Myung
Journal:  Korean J Physiol Pharmacol       Date:  2013-06-11       Impact factor: 2.016

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.